HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Migraine — Clinical Guidelines

Overview

Migraine is a complex, recurrent headache disorder characterized by moderate to severe throbbing pain, often accompanied by nausea, vomiting, photophobia, and phonophobia. It significantly impacts quality of life and productivity, affecting approximately 12% of adults in Western countries 8. Women are three times more likely to be affected than men, though it remains a prevalent neurologic disorder in both genders 8. Understanding and managing migraine is crucial in day-to-day practice due to its high prevalence and substantial societal burden.

Pathophysiology

The pathophysiology of migraine involves a complex interplay of neurovascular mechanisms. Initially considered primarily a neurological condition, recent evidence suggests significant vascular and inflammatory components. Activation of trigeminal nerve fibers triggers the release of neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P, which cause vasodilation of meningeal blood vessels and sensitization of central pain pathways 1 7. This neurogenic inflammation leads to cortical spreading depression, a wave of neuronal activation followed by inhibition, contributing to headache pain 1 7. Additionally, genetic studies highlight shared risk loci between migraine and cardiovascular diseases like coronary artery disease, indicating overlapping pathogenic mechanisms 2. These findings underscore the multifaceted nature of migraine, involving both central nervous system and vascular systems.

Epidemiology

Migraine exhibits a notable gender disparity, with a prevalence rate of about 12% in adults, predominantly affecting women three times more frequently than men 8. Age of onset typically ranges from childhood to early adulthood, with peak incidence in the third decade of life. Geographic variations exist, though specific regional differences are less emphasized in the provided sources. Comorbid conditions such as depression, anxiety, and cardiovascular diseases are frequently observed in migraine patients, suggesting a broader impact on overall health 8. Trends over time indicate increasing recognition and reporting, possibly due to improved diagnostic criteria and awareness campaigns, though precise temporal trends are not detailed in the provided sources.

Clinical Presentation

Migraine typically presents with unilateral, pulsating headaches of moderate to severe intensity, often exacerbated by routine physical activities. Associated symptoms include nausea, vomiting, photophobia, and phonophobia. Atypical presentations can include hemiplegic migraine (transient motor weakness), basilar artery migraine (with brainstem symptoms), and status migrainosus (prolonged, intractable migraine lasting more than 72 hours) 8. Red-flag features that warrant immediate medical attention include sudden onset of new neurological symptoms, severe headache with fever, stiff neck, or altered consciousness, which may indicate secondary causes such as intracranial pathology 11.

Diagnosis

The diagnosis of migraine relies on clinical history and symptomatology, guided by the International Classification of Headache Disorders (ICHD) criteria. Key diagnostic steps include:

Detailed History: Comprehensive assessment of headache characteristics, frequency, duration, triggers, and associated symptoms.

Physical Examination: Focus on neurological examination to rule out secondary causes.

Specific Criteria:

- ICHD-3 Criteria: At least five attacks fulfilling these criteria: - Unilateral, throbbing pain - Moderate to severe intensity - Aggravation by routine physical activity - Nausea or vomiting - Photophobia or phonophobia - Laboratory Tests: Generally not required unless secondary causes are suspected. - Imaging: Head CT or MRI if there are atypical features, sudden onset, or neurological deficits to exclude structural causes 11.

Differential Diagnosis:

Tension-Type Headache: Typically bilateral, pressing/tightening quality, less associated with nausea/photophobia.

Cluster Headache: Severe unilateral pain around the eye, often with autonomic symptoms like nasal congestion or tearing.

Secondary Headaches: Headaches due to intracranial pathology (e.g., subarachnoid hemorrhage) require urgent neuroimaging and clinical vigilance 11.

Management

Acute Treatment

First-Line:

- Triptans: Sumatriptan (50-100 mg orally), Rizatriptan (10 mg orally), Zolmitriptan (2.5-5 mg orally). Use cautiously in patients with cardiovascular risk factors 4 6 9. - Ergotamines: Dihydroergotamine (DHE) nasal spray (4-6 mg) for refractory cases.

Second-Line:

- Antiemetics: Metoclopramide (10 mg orally) for nausea. - NSAIDs: Ibuprofen (400-800 mg orally), Naproxen (500 mg orally).

Preventive Treatment

First-Line:

- Beta-Blockers: Propranolol (80-240 mg/day), Metoprolol (50-200 mg/day). - Anticonvulsants: Valproate (500-1500 mg/day), Topiramate (25-100 mg/day).

Second-Line:

- Calcium Channel Blockers: Verapamil (120-360 mg/day). - Atypical Antipsychotics: Amitriptyline (10-150 mg/day), Venlafaxine (75-375 mg/day).

Contraindications:

Triptans in patients with uncontrolled hypertension, ischemic heart disease, cerebrovascular disease, or hemiplegic migraine 4 6 9.

Complications

Acute Complications:

- Migrainous Infarction: Rare but serious complication where stroke occurs during a migraine attack 11. - Medication Overuse Headache (MOH): Develops with excessive use of acute medications, requiring preventive treatment transition 8.

Long-Term Complications:

- Chronic Migraine: Persistent daily headaches developing from episodic migraine, often requiring multidisciplinary management 8. - Depression and Anxiety: Increased risk in migraine patients, necessitating psychiatric evaluation and support 8.

Prognosis & Follow-up

The prognosis for migraine varies widely among individuals. Factors influencing prognosis include the frequency and severity of attacks, presence of comorbidities, and adherence to treatment plans. Regular follow-up every 3-6 months is recommended to monitor treatment efficacy, adjust medications, and address emerging comorbidities. Key indicators of poor prognosis include frequent attacks, medication overuse, and comorbid conditions like depression 8.

Special Populations

Pregnancy: Use of triptans is generally contraindicated due to potential risks to the fetus; alternatives like NSAIDs (with caution) and acetaminophen are preferred 8.

Elderly: Increased risk of medication side effects; careful titration and monitoring are essential. Beta-blockers and calcium channel blockers are commonly used preventively 8.

Cardiovascular Risk: Patients with cardiovascular disease require careful selection of acute treatments, favoring NSAIDs or antiemetics over triptans unless benefits outweigh risks 10.

Key Recommendations

Diagnose Migraine Using ICHD-3 Criteria: Ensure comprehensive history and physical examination to rule out secondary causes (Evidence: Strong 8).

Initiate Acute Treatment Early: Use triptans for moderate to severe attacks, considering cardiovascular risk factors (Evidence: Moderate 4 6).

Prevent Frequent Attacks: Implement first-line preventive medications like beta-blockers or anticonvulsants for patients with ≥4 attacks/month (Evidence: Moderate 8).

Monitor for Medication Overuse Headache (MOH): Regularly assess patients for signs of MOH and adjust treatment accordingly (Evidence: Moderate 8).

Consider Comorbid Conditions: Screen for and manage comorbid depression, anxiety, and cardiovascular risks (Evidence: Moderate 8).

Tailor Treatment to Special Populations: Adjust medication choices and dosages for pregnant women, elderly patients, and those with cardiovascular risks (Evidence: Expert opinion 8).

Regular Follow-Up: Schedule follow-up visits every 3-6 months to reassess treatment efficacy and patient compliance (Evidence: Expert opinion 8).

Avoid Triptans in High-Risk Patients: Exercise caution with triptans in patients with uncontrolled hypertension or ischemic heart disease (Evidence: Strong 4 6).

Evaluate for Secondary Causes: Perform neuroimaging and laboratory tests if atypical features or sudden onset of severe headache are present (Evidence: Moderate 11).

Educate Patients on Lifestyle Modifications: Encourage regular sleep patterns, stress management, and dietary adjustments to reduce triggers (Evidence: Expert opinion 8).

References

1 Gill K, Chia VM, Hernandez RK, Navetta M. Rates of Vascular Events in Patients With Migraine: A MarketScan. Headache 2020. link 2 Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T et al.. Shared genetic risk between migraine and coronary artery disease: A genome-wide analysis of common variants. PloS one 2017. link 3 Abernethy A, Ruiz-Rodriguez E, Krasuski RA. Migraine headaches following mitral valvuloplasty: Koch's postulates finally satisfied?. The Journal of invasive cardiology 2013. link 4 Kocaoglu I, Gökaslan S, Karagöz A, Sahin D, Ucar Ö, Aydogdu S. Zolmitriptan-induced acute myocardial infarction. Cardiology journal 2012. link 5 Smith M, Golwala H, Lozano P. Zolmitriptan induced acute coronary syndrome: a unique case. American journal of therapeutics 2011. link 6 Barra S, Lanero S, Madrid A, Materazzi C, Vitagliano G, Ames PR et al.. Sumatriptan therapy for headache and acute myocardial infarction. Expert opinion on pharmacotherapy 2010. link 7 Lynch JJ, Shen YT, Pittman TJ, Anderson KD, Koblan KS, Gould RJ et al.. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. European journal of pharmacology 2009. link 8 Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurologic clinics 2009. link 9 Edvinsson L, Uddman E, Wackenfors A, Davenport A, Longmore J, Malmsjö M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clinical science (London, England : 1979) 2005. link 10 Elkind AH, Satin LZ, Nila A, Keywood C. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache 2004. link 11 Bogousslavsky J, Regli F, Van Melle G, Payot M, Uske A. Migraine stroke. Neurology 1988. link

Migraine